Zogenix Inc

Find Ratings Reports
ZGNX : NASDAQ : Health Care
$13.4 0.0 | 0.0%
Today's Range: 12.9 - 13.45
Avg. Daily Volume: 240900.0
07/24/17 - 4:00 PM ET

Financial Analysis


ZOGENIX INC's gross profit margin for the first quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. ZOGENIX INC is extremely liquid. Currently, the Quick Ratio is 4.42 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 41.83% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)2.79.21
EBITDA ($mil)-19.47-12.4
EBIT ($mil)-19.69-12.78
Net Income ($mil)-21.31-10.39


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)80.11142.19
Total Assets ($mil)209.34286.61
Total Debt ($mil)22.3420.76
Equity ($mil)101.12173.86


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin15.6518.56
EBITDA Margin-722.29-134.71
Operating Margin-730.19-138.82
Sales Turnover0.110.11
Return on Assets-38.5113.47
Return on Equity-78.7-24.01
Debt Q1 FY17 Q1 FY16
Current Ratio5.397.87
Debt/Capital0.180.11
Interest Expense0.580.6
Interest Coverage-34.12-21.37


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)24.8124.77
Div / share0.00.0
EPS-0.85-0.41
Book value / share4.087.02
Institutional Own % n/a n/a
Avg Daily Volume238604.0267079.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.34 indicates valuation on par with the S&P 500 average of 3.07 and a significant discount versus the industry average of 12.00. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, ZOGENIX INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ZGNX NM Peers 90.95   ZGNX NM Peers 20.53

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ZGNX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ZGNX's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ZGNX NM Peers 16.97   ZGNX NA Peers 0.67

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ZGNX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ZGNX 3.34 Peers 12.00   ZGNX -80.33 Peers 18.85

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ZGNX is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ZGNX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ZGNX 15.11 Peers 11.85   ZGNX -29.70 Peers 6.08

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ZGNX is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ZGNX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades